And it looks like it is way more reliable than 177Lu...
The FDA has granted Fast Track Designation to 67Cu-SAR-bisPSMA, a novel radiopharmaceutical therapy for metastatic castration-resistant prostate cancer (mCRPC). Preliminary data from the SECuRE trial show promising results, with 73% of patients experiencing PSA reductions and 45% seeing drops greater than 50%. Notably, a patient who received two doses of 8 GBq 67Cu-SAR-bisPSMA achieved complete remission, with undetectable PSA levels for 13 months.
Final trial results are expected in September 2026, and continued remission in early responders could signal a breakthrough for advanced prostate cancer treatment.